MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4203-4212

  Aghaee Bakhtiari, Seyed Hamid ^a,d,i   Arefian, Ehsan ^b,d   Naderi, Mahmood ^c,d   Noorbakhsh, Farshid ^e   Nodouzi, Vahideh ^a   Asgari, Mojgan ^f,g   Fard Esfahani, Pezhman ^a   Mahdian, Reza ^a   Soleimani, Masoud ^h  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h TARBIAT MODARES UNIVERSITY   (Iran)

ⁱ MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

JAK STAT pathway; MAPK pathway; miR 23a; miR 23b; Prostate cancer

Indexed keywords

INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MICRORNA; MICRORNA 23A; MICRORNA 23B; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; MIRN23 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ALGORITHM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; JAK GENE; LNCAP CELL LINE; MALE; MAPK GENE; MATHEMATICAL COMPUTING; NONHUMAN; PC3 CELL LINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN RNA BINDING; SCORING SYSTEM; STAT GENE; BIOLOGY; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASES; MALE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938977652     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3057-3     Document Type: Article

References (38)

1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Globocan 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11; in Cancer IAfRo (ed), 2013.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.
3. Lassi K, Dawson NA. Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives. Future Oncol. 2011;7:551–8.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
5. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99–110.
6. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S. The therapeutic potential of microRNAs in cancer. Cancer J. 2012;18:275–84.
7. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (spc3649) can inhibit the biogenesis of mir-122. Nucleic Acids Res. 2014;42:609–21.
8. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18:1121–6.
9. Bader AG. Mir-34—a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
10. Heyn H, Schreek S, Buurman R, Focken T, Schlegelberger B, Beger C. MicroRNA mir-548d is a superior regulator in pancreatic cancer. Pancreas. 2012;41:218–21.
11. Ritchie W, Rasko JE, Flamant S. MicroRNA target prediction and validation. Adv Exp Med Biol. 2013;774:39–53.
12. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, et al. Tarbase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012;40:D222–9.
13. Tan Gana NH, Victoriano AF, Okamoto T. Evaluation of online miRNA resources for biomedical applications. Genes Cells: Devoted Mol Cell Mech. 2012;17:11–27.
14. da Silva HB, Amaral EP, Nolasco EL, de Victo NC, Atique R, Jank CC, et al. Dissecting major signaling pathways throughout the development of prostate cancer. Prostate Cancer. 2013;2013:920612.
15. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.
16. Bradham C, McClay DR. P38 MAPK in development and cancer. Cell Cycle. 2006;5:824–8.
17. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008;118:3051–64.
18. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59:279–84.
19. Harrison DA. The jak/stat pathway. Cold Spring Harbor perspectives in biology 2012;4
20. Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, et al. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol. 2012;36:347–53.
21. Liu X, He Z, Li CH, Huang G, Ding C, Liu H. Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res: POR. 2012;18:17–23.
22. Aalinkeel R, Hu Z, Nair BB, Sykes DE, Reynolds JL, Mahajan SD, et al. Genomic analysis highlights the role of the JAK-STAT signaling in the anti-proliferative effects of dietary flavonoid-‘ashwagandha’ in prostate cancer cells. Evid Based Complement Alternat Med: eCAM. 2010;7:177–87.
23. Chiromatzo AO, Oliveira TY, Pereira G, Costa AY, Montesco CA, Gras DE, et al. miRNApath: a database of miRNAs, target genes and metabolic pathways. Genet Mol Res: GMR. 2007;6:859–65.
24. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40:W498–504.
25. Ritchie W, Flamant S, Rasko JE. mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. Bioinformatics. 2010;26:223–7.
26. Mohammadi-Yeganeh S, Paryan M, Mirab Samiee S, Soleimani M, Arefian E, Azadmanesh K, et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis. Mol Biol Rep. 2013;40:3665–74.
27. Aghaee-Bakhtiari SH, Arefian E, Soleimani M, Noorbakhsh F, Samiee SM, Fard-Esfahani P, Mahdian R. Reproducible and reliable real-time pcr assay to measure mature form of mir-141. Appl Immunohistochem Mol Morphol 2015;Epub Ahead of Print
28. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70:7027–30.
29. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA mir-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–5.
30. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem. 2005;280:36529–40.
31. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013;4:350–7.
32. Coppola V, De Maria R, Bonci D. Micrornas and prostate cancer. Endocrine-related cancer 2010;17:F1-17
33. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;72:6435–46.
34. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012;72:1093–103.
35. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12:33–40.
36. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497–505.
37. Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci. 2011;102:769–75.
38. Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M, et al. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J. 2010;277:3726–34.